Join us on Thursday, May 9, 2019, for the next Startup Series event, hosted by Bios Partners and UNTHSC that will highlight and educate our community on the importance of entrepreneurship in Fort Worth. This edition will feature the co-founders of ZS Pharma, Al Guillem and Jeff Keyser, who will tell us their story about how they built their pharmaceutical company that they sold to AstraZeneca for $2.7 billion in 2015.
Alvaro F. Guillem, Ph.D.
Al co-founded Renibus Therapeutics in 2015 as CEO. He is a veteran of the pharmaceutical industry with nearly 40 years of leadership experience in bringing new therapies to the market and readying pharmaceutical manufacturing facilities for commercial production at both well-established and startup companies. Al brings a deep knowledge and insight into pharmaceutical manufacturing across many dosage forms and manufacturing operations. Prior to Renibus Therapeutics, he held senior positions at Genzyme/Bone Care, Wyeth, and Boeringher Ingelheim, as well as at start-up companies such as Medeva Americas and Adams Respiratory Therapeutics (ARP), where he, along with other team members, brought the Mucinex product line to the market. ARP sold to Reckitt Benckiser for $2.3 billion dollars in 2007. Most recently Al co-founded and held the role of President and CEO for ZS Pharma, a start up company developing a product for hyperkalemia or high levels of potassium in the blood. ZS Pharma was sold to Astra Zeneca in 2015 for $2.7 billion.
Al holds a BS in chemistry from the University of Mary Washington and a Ph.D. in chemistry from Virginia Commonwealth University.
Dr. Donald Jeffrey Keyser
Dr. Keyser is a veteran of the pharmaceutical industry with 40 years of leadership experience in developing and commercializing new medical therapies. He has invented products leading to significant improvements in patient care and has numerous patents issued by the USPTO in healthcare. He has a track record of success in developing new companies from start-up, through IPO and M&A exits.
Dr. Keyser co-founded Renibus Therapeutics, a company developing novel therapies for the diagnosis, treatment and prevention of kidney disease. He is a member of the Renibus Board of Directors and Board Secretary. He is the President and Chief Operating Officer for the company. He is currently serving as the Chairman of the Board for Lantern Pharma.
Dr. Keyser co-founded ZS Pharma acquired by Astra Zeneca for $2.7 Billion. While at ZS Pharma he was a member of ZS Pharma’s Board of Directors and the Chief Operating Officer for the company. Dr. Keyser was the inventor of the Mucinex product line for Adams Respiratory Therapuetics. He developed and executed the R&D and Regulatory strategy for Adams Respiratory Therapuetics as Vice President of Development and Regulatory Affairs. Adams Respiratory Therapuetics was acquired by Reckitt Benckiser for $2.3 Billion. He was previously employed as Chief Compliance Officer & Vice President Regulatory Affairs, Encysive Pharmaceuticals, Vice President Technical & Regulatory Affairs, Medeva Americas, Sr. Director Regulatory Affairs, Marion Merrell Dow and Regulatory Principal, Abbott Laboratories.
Dr. Keyser received his Pharmacy degree from Creighton University, a Juris Doctorate from Creighton University, a MPA from the University of Missouri-Kansas City and a PhD in Economics from The University of Texas at Dallas.